| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on disposal of property and equipment | NaN | 0 | 0 | 0 |
| Net income (loss) | 137,162 | -5,397 | -27,518 | NaN |
| Expense (income) associated with warrant liabilities | NaN | NaN | 2 | 397 |
| Depreciation expense | 93 | 92 | 93 | 218 |
| Common shares issued for dividend on partner company's convertible preferred shares | NaN | 0 | 0 | 0 |
| Research and development - licenses acquired, expense | NaN | 0 | NaN | NaN |
| Bad debt expense | 30 | -41 | 76 | -246 |
| Gain from deconsolidation of subsidiary | NaN | 0 | 27,127 | NaN |
| Amortization of debt discount | 1,455 | 339 | 319 | 746 |
| Asset impairment loss | NaN | 0 | 0 | 0 |
| Accretion of partner company convertible preferred shares | NaN | 0 | 0 | 0 |
| Gain on termination of partner company lease | 0 | 0 | 0 | 394 |
| Loss on extinguishment of debt | NaN | 0 | 0 | NaN |
| Amortization of acquired intangible assets | 1,126 | 1,065 | 3,193 | NaN |
| Settlement of partner company payables | -76 | -731 | -577 | -796 |
| Reduction in the carrying amount of operating lease right-of-use assets | 480 | 476 | 496 | 971 |
| Stock-based compensation expense | 1,756 | 2,459 | 3,198 | 23,082 |
| Change in fair value of investment | 1,047 | 0 | 15,075 | NaN |
| Change in fair value of partner company derivative liability | -7,085 | NaN | NaN | NaN |
| Change in fair value of partner companies' warrant liabilities | -1 | 398 | NaN | NaN |
| Accounts receivable | -4,761 | 11,759 | 2,415 | 5,167 |
| Inventory | -332 | -2,194 | -1,034 | -1,579 |
| Other receivables - related party | 358 | 16 | -416 | 387 |
| Prepaid expenses and other current assets | -56 | 2,553 | -1,744 | -2,355 |
| Other assets | 339 | -21 | -17 | -292 |
| Accounts payable and accrued expenses | 45,937 | 2,678 | -2,828 | -7,821 |
| Income taxes payable | 5,062 | -649 | 21 | 52 |
| Lease liabilities | -550 | -552 | -549 | -1,125 |
| Other long-term liabilities | 887 | -169 | -1,973 | 464 |
| Net cash provided by (used in) operating activities | 203,851 | -12,544 | -6,110 | -47,123 |
| Acquired intangible assets | NaN | 0 | NaN | NaN |
| Proceeds from sale of property and equipment | 0 | 0 | 0 | 1,165 |
| Proceeds from sale of subsidiary interests | NaN | NaN | NaN | 6,086 |
| Net cash increase upon deconsolidation of subsidiary | NaN | 0 | 8,956 | NaN |
| Stock and warrants issued for exchange of partner company preferred shares | NaN | 0 | 0 | 0 |
| Net cash provided by investing activities | 0 | 0 | 2,870 | 7,251 |
| Proceeds from long-term debt, net | NaN | 55 | -130 | NaN |
| Payment of series a perpetual preferred stock dividends | NaN | 0 | 0 | 0 |
| Proceeds from partner company's long-term debt, net | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock for public offering, net | NaN | 0 | 0 | 0 |
| Partner company's redemption of preferred shares | NaN | 0 | 0 | 265 |
| Proceeds from issuance of common stock for at-the-market offering, net | 0 | 0 | 0 | 1,008 |
| Proceeds from issuance of common stock under espp | 0 | 44 | 0 | 43 |
| Exercise of warrants for cash | 1,218 | 368 | 1,686 | 593 |
| Proceeds from partner companies' espp | 148 | 0 | 118 | 99 |
| Partner company's dividends declared and paid | 0 | 166 | 166 | 332 |
| Exchange of partner company preferred shares | 165 | NaN | NaN | NaN |
| Redemption of partner company preferred shares | 14,170 | NaN | NaN | NaN |
| Proceeds from partner companies' equity offerings and warrant exercises, net | 0 | 40 | 7,247 | 54,334 |
| Proceeds from partner companies' at-the-market offering, net | 0 | 5,421 | 6,891 | 6,740 |
| Proceeds from exercise of partner company's options, net | 72 | 0 | NaN | NaN |
| Repayment of oaktree note and debt issuance costs | 14,494 | 55 | 574 | 4,932 |
| Repayment of partner company installment payments - licenses | 0 | 0 | 0 | 625 |
| Net cash provided by (used in) financing activities | -27,391 | 5,707 | 15,072 | 56,663 |
| Net increase in cash and cash equivalents and restricted cash | 176,460 | -6,837 | 11,832 | 16,791 |
| Cash and cash equivalents and restricted cash at beginning of period | 80,601 | 87,438 | 58,815 | NaN |
| Cash and cash equivalents and restricted cash at end of period | 257,061 | 80,601 | 87,438 | NaN |
Fortress Biotech, Inc. (FBIOP)
Fortress Biotech, Inc. (FBIOP)